文献速递前列腺癌

PI-RADS 3 磁共振病灶在穿刺与根治标本中的病理特征

Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
PubMed 文献 · BJU Int · 2021-08-22

基于 150 例 PI-RADS 3 患者的前瞻性数据库,分析系统穿刺联合融合靶向穿刺及根治性前列腺切除标本的病理特征。结果显示靶向穿刺阴性率 20.7%,根治标本中 Grade Group ≥3 和 pT3 分别占 36.7% 和 38.7%,升级率 38.2%。PSAD 和靶向穿刺 csPCa 是不利病理的独立预测因素。

要点

  • PI-RADS 3 病灶中近 40% 根治标本具有侵袭性病理特征。
  • 靶向穿刺阴性率 20.7%,穿刺与根治分级一致率仅 38.0%。
  • PSAD 和靶向穿刺 csPCa 是不利病理的独立预测因素。

核心结论

  • PI-RADS 3 病灶中近 40% 病例在根治标本中表现出侵袭性特征。
  • PSAD 和靶向穿刺检出 csPCa 是高分级和/或包膜外疾病的独立预测因素。
  • 系统穿刺联合靶向穿刺较单用靶向穿刺改善分级预测。

研究设计与样本

  • 前瞻性数据库纳入 150 例 PI-RADS 3 且接受系统穿刺(中位 12 针)联合融合靶向穿刺(中位 3 针)后行根治性前列腺切除的患者。
  • 临床显著前列腺癌定义为 Grade Group ≥2。
  • 主要终点为根治标本中的不利病理特征。

主要发现

  • 靶向穿刺阴性率为 20.7%。
  • 根治标本中 Grade Group ≥3 占 36.7%,pT3 期占 38.7%。
  • 穿刺与根治标本间升级率为 38.2%,靶向穿刺与根治标本 Grade Group 一致率仅 38.0%。
  • 不利疾病(pT3-4 和/或最终 Grade Group 3-5)的两个独立预测因素为 PSAD(P = 0.001)和靶向穿刺存在 csPCa(比值比 3.7;P = 0.001)。
  • PSAD 在 0.15–0.20 和 >0.20 ng/mL/g 时不利疾病风险分别增加 2.3 倍和 5.8 倍;5 年生化复发无生存率为 93.2%。

关键数值与推荐

  • 临床显著前列腺癌定义为 Grade Group ≥2。
  • 不利疾病定义为 pT3-4 和/或最终 Grade Group 3-5。
  • 靶向穿刺存在 csPCa 的比值比为 3.7(P = 0.001)。
  • PSAD 0.15–0.20 ng/mL/g 和 >0.20 ng/mL/g 分别对应不利疾病风险增加 2.3 倍和 5.8 倍。

临床怎么用

  • 对 PI-RADS 3 病灶应结合 PSAD 和靶向穿刺结果评估不利病理风险。
  • 系统穿刺联合靶向穿刺可改善分级预测,避免单用靶向穿刺的遗漏。
  • PSAD >0.20 ng/mL/g 或靶向穿刺检出 csPCa 提示需警惕高分级或包膜外疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the whole pathology spectrum of Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions, identified on magnetic resonance imaging, using systematic (SB), targeted biopsy (TB) and radical prostatectomy (RP) specimen analysis. METHODS: From a prospective database of patients undergoing RP after a combination of SB (median 12 cores) and fusion TB (median 3 cores), we included 150 PI-RADS 3 cases. Clinically significant prostate cancer (csPCa) was defined by a Grade Group 2 or more. The primary endpoints were unfavourable features in RP specimens. RESULTS: Targeted biopsy was negative in 20.7% of patients. Final Grade Group 3 or more and a pT3 stage was reported in 36.7% and 38.7% of RP specimens. The upgrading rate was 38.2% between biopsy and RP specimens. The concordance rate between Grade Group on TB and RP was only 38.0%. The two independent predictive factors for unfavourable disease (pT3-4 and/or final Grade Group 3-5) were prostate-specific antigen density (PSAD; P = 0.001) and presence of csPCa on TB (odds ratio 3.7; P = 0.001). The risk of unfavourable disease was increased 2.3-fold and 5.8-fold, respectively, for patients with a PSAD between 0.15 and 0.20, and a PSAD >0.20 ng/mL/g. The 5-year biochemical recurrence-free survival rate was 93.2%. CONCLUSIONS: PI-RADS 3 lesions exhibited aggressive features in almost 40% of cases. PSAD and presence of csPCa on TB are independent predictive factors for high-grade and/or extraprostatic disease. A combination of SB and TB improve grade prediction compared to use of TB alone.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Rahota RG, Diamand R, Malavaud B, et al. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens. BJU Int. 2021. PMID: 34358405. doi:10.1111/bju.15563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。